Nothing Special   »   [go: up one dir, main page]

Silani et al., 2011 - Google Patents

The diagnosis of Amyotrophic lateral sclerosis in 2010

Silani et al., 2011

View PDF
Document ID
13142740908656651301
Author
Silani V
Messina S
Poletti B
Morelli C
Doretti A
Ticozzi N
Maderna L
Publication year
Publication venue
Archives italiennes de biologie

External Links

Snippet

Abstract The diagnosis of Amyotrophic Lateral Sclerosis (ALS) remains in 2010 clinical with neurophysiological support in absence of specific biomarker (s). The disease is diverse in its presentation, cause, and progression. Treatable mimic syndromes must be excluded before …
Continue reading at architalbiol.org (PDF) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Similar Documents

Publication Publication Date Title
Silani et al. The diagnosis of Amyotrophic lateral sclerosis in 2010
Thome et al. Biomarkers for attention-deficit/hyperactivity disorder (ADHD). A consensus report of the WFSBP task force on biological markers and the World Federation of ADHD
Fakhoury Autistic spectrum disorders: A review of clinical features, theories and diagnosis
Grudzien et al. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease
Rapoport et al. The neurodevelopmental model of schizophrenia: update 2005
Kiernan et al. Amyotrophic lateral sclerosis
Halperin et al. Serotonin, aggression, and parental psychopathology in children with attention-deficit hyperactivity disorder
Monastero et al. Cognitive impairment in Behçet's disease patients without overt neurological involvement
Oades Role of the serotonin system in ADHD: treatment implications
Dekker et al. Serum MHPG strongly predicts conversion to Alzheimer's disease in behaviorally characterized subjects with Down syndrome
WO2017106363A1 (en) Refining diagnosis and treatment of complex multi-symptom neurological disorders
Orsini et al. Cognitive impairment in neuromuscular diseases: a systematic review
Chiò et al. Comorbidity between CIDP and diabetes mellitus: only a matter of chance?
Sel et al. Nonketotic hyperglycinemia: Clinical range and outcome of a rare neurometabolic disease in a single-center
Peterson et al. Biological basis of childhood neuropsychiatric disorders
Jelen et al. Variants in the zinc transporter-3 encoding gene (SLC30A3) in schizophrenia and bipolar disorder: Effects on brain glutamate–A pilot study
Moncrieff Hemispheric asymmetry in pediatric developmental disorders: Autism, attention-deficit/hyperactivity disorder, and dyslexia
Schottlaender et al. Multiple system atrophy: clinical, genetics, and neuropathology
Mazur-Kolecka et al. Altered development of neuronal progenitor cells after stimulation with autistic blood sera
Yuan et al. Clinical features and progress in diagnosis and treatment of amyotrophic lateral sclerosis
Wu et al. Cognitive impairment, neuroimaging abnormalities, and their correlations in myotonic dystrophy: a comprehensive review
Wei et al. Differential neuropsychiatric associations of plasma biomarkers in older adults with major depression and subjective cognitive decline
Love et al. Psychiatric Diseases
Patwardhan Gender-Specific Differences in Cognitive Functions and Alzheimer’s Risk in Type 2 Diabetes Mellitus
Blandiaux et al. PCI & Auditory ERPs for the diagnosis of disorders of consciousness: a EEG-based methods comparison study